UNSPSC 51281627: Amikacin

This classification denotes an aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 84319SGC3C. European Medicines Agency schedules Amikacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05431MIG. Amikacin generally arises in the molecular formula C22H43N5O13.

UNSPSC 51281627 Amikacin is a Commodity code for a specific injectable antibiotic, but the recent state and local opportunities posted under this code do not reflect purchases of amikacin itself. Instead, the Illinois Department of Public Health and Seminole County, Florida have solicited pharmaceutical products through cooperative purchasing vehicles and competitive bids that fall outside amikacin's scope — the Illinois contract awarded to Chartwell Rx LLC covers Doxycycline Hyclate and Ciprofloxacin Hydrochloride, while the Seminole County procurement seeks Naloxone and drug deactivation systems. State and local health departments and county health agencies are the primary issuing bodies using this code tier, typically procuring through piggyback contracts under multi-state cooperative consortia (such as MMCAP Infuse) or direct competitive solicitations. The products sourced tend to be emergency-response pharmaceuticals, public health interventions, and related medical supplies rather than a single standardized commodity.

The code shows activity primarily in Florida and Illinois based on recent postings. The Illinois Department of Public Health awarded its piggyback pharmaceutical contract on August 28, 2026, through an Invitation for Bid process with a $2,999,999.11 total value over 12 months plus two renewal options; the contract supports quarterly or as-needed warehouse supply chains to support public health emergencies. Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building in Sanford, including a two-year initial term with one-year renewal option. The mismatch between the amikacin commodity name and the actual pharmaceuticals being procured suggests either miscoding at the source or a broader antimicrobial and emergency-response pharmaceutical family grouping in state and local procurement systems; prospective vendors should verify that opportunities tagged under this code align with their product line before investing in pursuit.